NEW YORK--(BUSINESS WIRE)--Marathon Pharma, LLC today announced positive results from 2 separate - IPRIVASK® studies presented at the International Congress for Joint Reconstruction (ICJR) Transatlantic Meeting, held in New York City.
Study-1: This Post-Hoc analysis evaluated the safety and efficacy of Iprivask in several high-risk patient subgroups of the pivotal registration multicenter trial comparing desirudin to enoxaparin, in patients undergoing elective total hip replacement (THR) surgery (Eriksson et al, 1997). Results from this analysis demonstrated that patients with various high-risk conditions (e.g. age>65, obesity, cancer, varicose veins, previous VTE) undergoing elective hip replacement, had favorable odds ratio’s for venous thromboembolism (VTE) incidence with desirudin compared with enoxaparin.
Help employers find you! Check out all the jobs and post your resume.
